The U.S. Food and Drug Administration (FDA) approved amivantamab (Rybrevant) on May 21, 2021.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

Pegcetacoplan (Empaveli) was approved by the U.S. Food and Drug Administration (FDA) on May 14, 2021, for the treatment of PNH.

Eli Lilly and Company along with Morphic Holding, Inc. have revealed a formal agreement in which Lilly will purchase Morphic.

Loncastuximab tesirine (Zynlonta) was approved by the U.S. Food and Drug Administration (FDA) on April 23, 2021.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

Viloxazine (Qelbree) was approved by the U.S. Food and Drug Administration (FDA) on April 2, 2021.

Ligand Pharmaceuticals Incorporated revealed that it has finalized a definitive contract to purchase APEIRON Biologics AG.

Dasiglucagon (Zegalogue) was approved by the U.S. Food and Drug Administration (FDA) on March 22, 2021.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

Ponvory (ponesimod) was approved by the U.S. Food and Drug Administration (FDA) on March 18, 2021.

iTeos Reports Initial Patient Dosed in GALAXIES Lung-301 Phase 3 Trial, Securing $35 Million Milestone Payment from GSK.